Drug Information

Drug General Information
Drug ID
D0HO2T
Former ID
DCL000479
Drug Name
AZD7325
Drug Type
Small molecular drug
Indication Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] Phase 2 [522519], [542687]
Company
AstraZeneca
Formula
C19H19FN4O2
InChI
InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25)
InChIKey
KYDURMHFWXCKMW-UHFFFAOYSA-N
PubChem Compound ID
23581869
PubChem Substance ID
46387126, 56006577, 131280825, 141750726, 163367505, 223366045, 223370289, 224103717, 228123802, 241181130, 244246808
Target and Pathway
Target(s) Glutamate receptor AMPA subtype Target Info Agonist [550288]
References
Ref 522519ClinicalTrials.gov (NCT00807937) Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325. U.S. National Institutes of Health.
Ref 542687(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7712).
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).